Anhui Fengyuan Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	7.7yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Apr 17

CEO

Anhui Fengyuan Pharmaceutical has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jun Li	Financial Director	7.1yrs	CN¥398.00k	0.12% CN¥ 3.2m
Shaoyi Zhang	Deputy GM & Director	17yrs	CN¥576.00k	0.090% CN¥ 2.5m
Zhenhong Lu	Deputy GM & Director	3.6yrs	CN¥462.00k	0.11% CN¥ 2.9m
Tianle Ru	GM & Director	8.3yrs	CN¥684.00k	0.30% CN¥ 8.2m
Jinchao Duan	Deputy GM & Director	4.8yrs	CN¥324.00k	0.060% CN¥ 1.6m
Jun Zhang	Secretary of the Board & Non-Independent Director	25.5yrs	CN¥330.00k	0.14% CN¥ 3.7m
Guo Kun Li	Deputy General Manager	11yrs	CN¥386.00k	0.060% CN¥ 1.6m
Shuang Qing Yin	Deputy General Manager	4.8yrs	CN¥368.00k	0.090% CN¥ 2.5m

7.7yrs

Average Tenure

49.5yo

Average Age

Experienced Management: 000153's management team is seasoned and experienced (7.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shaoyi Zhang	Deputy GM & Director	9.5yrs	CN¥576.00k	0.090% CN¥ 2.5m
Zhenhong Lu	Deputy GM & Director	8.1yrs	CN¥462.00k	0.11% CN¥ 2.9m
Tianle Ru	GM & Director	1.8yrs	CN¥684.00k	0.30% CN¥ 8.2m
Jinchao Duan	Deputy GM & Director	1.8yrs	CN¥324.00k	0.060% CN¥ 1.6m
Jun Zhang	Secretary of the Board & Non-Independent Director	3.9yrs	CN¥330.00k	0.14% CN¥ 3.7m
Hongman He	Chairman of the Board	16.1yrs	CN¥760.00k	0.45% CN¥ 12.3m
Yue'e Hu	Chairman of Supervisory Board	1.8yrs	CN¥420.00k	no data
Weidong Zhu	Independent Director	4.8yrs	CN¥60.00k	no data
Jiemiao Chen	Independent Director	4.8yrs	CN¥60.00k	no data
Jinsheng Hu	Non-Employee Supervisor	4.8yrs	no data	no data
Cisheng Wu	Independent Director	1.8yrs	CN¥30.00k	no data
Hui Yan Sun	Supervisor	4.8yrs	no data	no data

4.8yrs

Average Tenure

55yo

Average Age

Experienced Board: 000153's board of directors are considered experienced (4.8 years average tenure).

Anhui Fengyuan Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Less than half of directors are independent

High number of new directors

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

High number of new and inexperienced directors

Recent updates

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.14 in 1Q 2023)

Now 23% overvalued

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 18%

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.17 in 2Q 2022)

Anhui Fengyuan Pharmaceutical Announces Cash Dividend for 2022

Full year 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.37 in FY 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.085 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 2Q 2021)

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 05 July 2022

Anhui Fengyuan Pharmaceutical Co., Ltd. Approves Cash Distribution for 2021

Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.041 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.26 in FY 2019)

Investor sentiment improved over the past week

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥6.62

Investor sentiment deteriorated over the past week

New 90-day low: CN¥7.79

New 90-day low: CN¥8.07

New 90-day low: CN¥8.22

Third quarter earnings released

First half earnings released

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥12.49

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age